Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662038 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,058
- Enrollment target
NCT00662038 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 1,058 participants.
The verdict
NCT00662038, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,058 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
Interventions
- DRUG pirfenidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,058 participants |
| Start Date | 2008-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662038
The ClinicalTrials.gov registry entry for NCT00662038 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,058 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pirfenidone is the first listed.
NCT00662038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662038 about?
NCT00662038 is a clinical study titled "Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)". This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical tr...
What is the current status of trial NCT00662038?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,058 participants. The study started on 2008-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00662038?
The interventions under investigation include: pirfenidone (DRUG).
Who is sponsoring clinical trial NCT00662038?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.